ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association …
CA Warnes, RG Williams, TM Bashore, JS Child… - Circulation, 2008 - Am Heart Assoc
The recommendations listed in this document are, whenever possible, evidence-based.
Unlike other ACC/AHA practice guidelines, there is not a large body of peer-reviewed …
Unlike other ACC/AHA practice guidelines, there is not a large body of peer-reviewed …
ACC/AHA 2008 guidelines for the Management of Adults with Congenital Heart Disease: executive summary: a report of the American College of Cardiology/American …
CA Warnes, RG Williams, TM Bashore, JS Child… - Circulation, 2008 - Am Heart Assoc
The recommendations listed in this document are, whenever possible, evidence-based.
Unlike other ACC/AHA practice guidelines, there is not a large body of peer-reviewed …
Unlike other ACC/AHA practice guidelines, there is not a large body of peer-reviewed …
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010) The Task Force on the Management of Grown-up Congenital Heart …
Endorsed by the Association for European … - European heart …, 2010 - academic.oup.com
The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …
for personal and educational use only. No commercial use is authorized. No part of the ESC …
Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension
K Dimopoulos, R Inuzuka, S Goletto, G Giannakoulas… - Circulation, 2010 - Am Heart Assoc
Background—Advanced therapy (AT) for pulmonary arterial hypertension in the context of
congenital heart disease (Eisenmenger syndrome) improves pulmonary hemodynamics …
congenital heart disease (Eisenmenger syndrome) improves pulmonary hemodynamics …
Pulmonary vascular disease in adults with congenital heart disease
GP Diller, MA Gatzoulis - Circulation, 2007 - Am Heart Assoc
Pulmonary arterial hypertension of variable degree is commonly associated with adult
congenital heart disease. Depending on size and location of the underlying cardiac defect …
congenital heart disease. Depending on size and location of the underlying cardiac defect …
Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension
M Beghetti, N Galiè - Journal of the American College of Cardiology, 2009 - jacc.org
Eisenmenger syndrome (ES), the most advanced form of pulmonary arterial hypertension
(PAH) associated with congenital heart disease, is a devastating condition that has a …
(PAH) associated with congenital heart disease, is a devastating condition that has a …
Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome
N Galie, A Manes, M Palazzini, L Negro, A Marinelli… - Drugs, 2008 - Springer
A large proportion of patients with congenital heart disease (CHD), in particular those with
relevant systemic-to-pulmonary shunts, will develop pulmonary arterial hypertension (PAH) …
relevant systemic-to-pulmonary shunts, will develop pulmonary arterial hypertension (PAH) …
Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study
BACKGROUND: Bosentan, an oral endothelin ETA/ETB receptor antagonist, improves
hemodynamics and exercise capacity in patients with Eisenmenger syndrome but longer …
hemodynamics and exercise capacity in patients with Eisenmenger syndrome but longer …
Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease
T Becker-Grünig, H Klose, N Ehlken, M Lichtblau… - International journal of …, 2013 - Elsevier
Background The objective of this prospective study was to assess the efficacy of exercise
training as add-on to medical therapy in patients with congenital heart disease associated …
training as add-on to medical therapy in patients with congenital heart disease associated …
Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
O Sitbon, AV Noordegraaf - European Respiratory Review, 2017 - Eur Respiratory Soc
Epoprostenol was the first therapy to be approved for the treatment of pulmonary arterial
hypertension (PAH). In the 20 years since the introduction of this prostacyclin analogue, the …
hypertension (PAH). In the 20 years since the introduction of this prostacyclin analogue, the …